The FDA has granted Breakthrough Therapy designation to peginterferon lambda (Lambda; Eiger BioPharmaceuticals) for the treatment of hepatitis delta virus (HDV) infection.
Optimized, commercial enzyme immunoassays may be able to diagnose hepatitis B virus using oral fluid samples.
The development of Guillain-Barre syndrome (GBS) has demonstrated an association with existing hepatitis C virus (HCV) infection and mixed cryoglobulinemia, according to a case study published in BMC Infectious Diseases. The subtype severe acute motor sensory axonal neuropathy was classified as a subtype of GBS through electromyography, associated with severe clinical presentation. Researchers noted that only…
Data published in Clinical Infectious Diseases revealed that by 2014, less than one-third of individuals aged 18 to 49 years who were at risk for hepatitis B virus (HBV) exhibited hepatitis B surface antibody levels indicative of protection (anti-HBs >10 mIU/mL). Data from the 2003 to 2014 National Health and Nutrition Examination Surveys were used…
The United States Preventative Service Task Force has issued a statement that reaffirms its 2009 recommendations for screening pregnant women for hepatitis B virus.
The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has voted to recommend that pediatric patients (2 to 18 years old) who have not previously received hepatitis A vaccine be routinely vaccinated at any age. Currently, the CDC recommends routine hepatitis A vaccination for children 12 to 23 months of…
Direct-acting antiviral (DAA) exposure may not be associated with higher rates of any serious adverse events when used for hepatitis C virus (HCV) treatment, according to a study published in JAMA Network Open. At this time, there are approximately 2.4 million individuals living in the United States who are infected with HCV. Further, 28% of…
Investigators sought to determine the risk for Parkinson disease development in patients with hepatitis C virus who received antiviral treatment and in patients who did not receive this treatment.
The novel method of lateral flow immunoassay may be a cost-effective way to identify patients with chronic hepatitis B virus infection.
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
Advantage of interferon-based antiviral therapy reached statistical significance at five-year follow-up
In a large cohort of patients with HCV, the use of DAA was associated with significantly lower incidence and risk for subsequent diabetes.
Hepatitis B e antigen prevalence and other hepatitis B virus markers decline with age and differ by race with HBeAg persisting longer among Asian people.
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
In onsite HCV care delivered to PWID in opioid agonist therapy programs, a greater adherence was associated with directly observed therapy when compared with self-administered individual treatment.
An 8- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with HCV infection after liver transplantation.
Treatment with DAAs before liver transplantation is associated with improved outcome and appears to be safe in patients with decompensated hepatitis C-related cirrhosis.
There was no significant effect of maternal tenofovir use for the prevention of mother-to-child transmission of HBV on bone mineral density in either the mother or child 1 year after delivery.
Patients with TB and HBV co-infection should be given antiviral treatment for HBV when anti-TB therapy is initiated.
The impact of direct-acting antiviral therapy was investigated in a large cohort of patients in complete remission following treatment of hepatitis C-related HCC.